China approves Brii COVID treatment in adults, teens – Community News

China approves Brii COVID treatment in adults, teens

A medical staff member in PPE advises people outside a nucleic testing site at a hospital, following an outbreak of the coronavirus disease (COVID-19), in Beijing, China, Dec. 28, 2020. REUTERS/Thomas Peter

BEIJING, Dec. 8 (Reuters) – China’s medical products regulatory agency said on Wednesday it had approved the use of Brii Biosciences’ neutralizing antibody cocktail (2137.HK) for COVID-19, the first treatment of its kind against the virus seen the go-forward in the country.

The combination of BRII-196/BRII-198 showed a 78% reduction in hospitalization and death in unhospitalized COVID-19 patients at high risk of developing serious disease in a phase III clinical trial, Brii said in October.

A Brii subsidiary’s drug is approved to treat mild COVID-19 and “normal-type” disease with a high risk of hospitalization or death in adults and minors ages 12-17, the National Medical Products Administration says .

The company has filed for emergency use for the treatment in the US, where similar products from Regeneron Pharmaceuticals and Eli Lilly have been approved.

Before approval, Brii’s treatment had already been used in nearly 700 patients in China as of Nov. 5 amid local outbreaks, the company said.

Register now for FREE unlimited access to

Reporting by Roxanne Liu and Ryan Woo; Editing by Jan Harvey and Alexander Smith

Our Standards: The Thomson Reuters Trust Principles.

About the author


Add Comment

Click here to post a comment